New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Hea... (gression ofatherosclerosis to prevent on...)

New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Heart Failure

Date:11/5/2007

gression of atherosclerosis to prevent one of its worst consequences, heart failure."

"The CORONA study was a novel and challenging study and demonstrates our commitment to advancing medical knowledge by investigating the effects of CRESTOR in challenging patient populations with unmet medical need. The CORONA study included patients with advanced heart failure on optimal treatment who were not candidates for statin therapy in the view of the investigators and which sought to answer the question of whether or not statins provide additional benefit or might even be harmful in this population. As a result of this study, AstraZeneca has provided new scientific information to help answer these important questions", said Elisabeth Bjork, Global Medical Science Director for CRESTOR.

CORONA (COntrolled ROsuvastatin MultiNAtional Study in Heart Failure) was a long-term, randomized, placebo-controlled study of more than 5,000 patients with chronic, symptomatic, systolic heart failure (NYHA II-IV) of ischemic origin, whom investigators felt did not need lipid-lowering therapy. The study was designed to evaluate the effects of adding CRESTOR 10 mg to optimized treatment for heart failure on cardiovascular mortality and morbidity and overall survival.

CRESTOR 10 mg was well tolerated in over 2,500 patients during the study, with a safety profile similar to placebo. The frequency and type of adverse events were comparable in all treatment groups throughout the study. CORONA was conducted in 21 countries.

CORONA is a part of AstraZeneca's extensive GALAXY clinical trials program, designed to address important unanswered questions in statin research. Currently, more than 69,000 patients have been recruited from 55 countries worldwide to participate in the GALAXY Program.

CRESTOR has now received regulatory approvals in over 90 countries. Over 11 million patients have been prescribed CRESTOR worldwide. Data from clinical trials and real world use shows
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. AAHC Examines Nations Clinical Trials Infrastructure
2. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
3. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
4. DNA Test Predicts Harmful Effects of Cancer Drug
5. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
6. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
7. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
8. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
9. New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects

Post Your Comments:

(Date:12/16/2009)... December 16 Scientists at,deCODE genetics, Inc. ... the,discovery of a version of a common single-letter ... with a major impact on susceptibility to type ... is not only large, but unusual:,if an individual ... risk of,T2D by more than 30% compared to ...

(Date:12/16/2009)... YORK, December 16 International, ... publication of GFT505 (80 mg/day),data presented ... internationally,recognized expert scientists and clinicians critically ... continuing role of generic lipid-modifying,treatments, fenofibrate ... is commonly observed in patients with ...

(Date:12/16/2009)... RealMed has been ranked the #1 Claims ... Top 20 Best in KLAS Awards: Software ... a dynamic revenue cycle management solution providing ... providers and all payers. KLAS ... vendor performance measurement in the software, professional ...

[0] deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin [0] International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia [0] RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service

... Jan. 25 ,Takeda Pharmaceutical Company Limited (TSE: 4502) and ... has dosed the first patient in,the United States in ... the treatment of anemia in cancer patients undergoing,chemotherapy., ... Affymax are,jointly developing Hematide, and Affymax is now conducting ...

... U.S. Data Highlights Oral Xeloda versus Standard Infusional Chemotherapy ... in Gastroesophageal and Colorectal Cancers -, NUTLEY, ... 33 abstracts involving its oral chemotherapy Xeloda(R) have been,accepted for ... Jan. 25 to 27., Five poster presentations based on ...

Other Medicine Technology:Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia 2 Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia 3 Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium 2 Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium 3

Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium

(Date:12/16/2009)... Md., Dec. 16 For wounded ... Medical Center in Washington, D.C., the holidays can be ... able to travel home rely more than ever on ... This week, calling home just got easier for ... free calling cards, which will provide hundreds of minutes ...

(Date:12/16/2009)... possibly deadly, attack is long-term goal, researchers say ... developed a tool to predict whether a patient will ... first stroke. , "This is an important new tool ... second stroke soon after a first stroke are more ... Ay, of Massachusetts General Hospital and Harvard Medical School, ...

(Date:12/16/2009)... health and environmental concerns about the emerging nanotechnology industry, ... behavior of nanoparticles in municipal sewage treatment plants ... published in ACS, journal Environmental Science & Technology ... Ecology and Hydrology and colleagues note that experts predict ... less than 1/1000th the width of a human hair ...

(Date:12/16/2009)... Ensure and Encourage Access to Quality, Cost-Effective Care , ... ... of Congress have debated the best ways to rein in runaway ... reform. An important part of the ongoing discussion includes how ... care providers besides doctors of medicine (MDs) or osteopathy (DOs). ...

(Date:12/16/2009)... Stress Reduction Therapy or NSRTSM is found very effective in ... as allergies, asthma, migraines, chronic fatigue and a wide array ... country are using this holistic therapy including over 50 branded ... ... Minneapolis, MN (Vocus) December 14, 2009 -- BioVeda Health ...

Breaking Medicine News(10 mins):Health News:Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital 2 Health News:New Stroke Tool May Predict Early Recurrence 2 Health News:Behavior modification could ease concerns about nanoparticles 2 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4 Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 2 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 3 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 4 Health News:BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening 5

[0] Verizon Wireless Donates $10,000 in Long-Distance Calling Cards to Soldiers at Walter Reed Hospital [0] New Stroke Tool May Predict Early Recurrence [0] Behavior modification could ease concerns about nanoparticles [1] Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs [0] BioVeda Health and Wellness Center of Chanhassen, MN Announces Its Grand Opening

... LOS ANGELES, March 9 /PRNewswire-USNewswire/ -- ... diagnostic imaging center, offers advanced technology that enables ... resulting in better outcomes for patients.On the campus ... Los Angeles Advanced Imaging combines the comforts of ...

... therapies such as radiotherapy, chemotherapy, and retinoic acid (RA). ... prognosis for patients is often poor. However, Vincent Hearing ... National Institutes of Health in Bethesda, Maryland, have now ... to RA, suggesting that this noncytotoxic therapeutic approach may ...

... PRESIDENT AND CEO RESIGNS -ADDISON, Texas, March 9 ULURU ... P. Gray as Chief Executive Officer of the Company effective ... Gray will continue to serve as a Director of the ... of Directors to assume the position of President and Chief ...

... /PRNewswire/ -- SecureWorks(R), one of the ... with Columbian-based ETEK International to extend its security services ... One of South America,s leading security providers, ETEK will ... include, among others, Intrusion Prevention and Detection, Security and ...

... MOUNTAIN VIEW, Calif., March 9 Based on ... market, Frost & Sullivan recognizes ValveXchange, Inc. with ... Innovation of the Year Award for developing the ... two-part bioprosthetic tissue valve, the patented system promises ...

... March 9 ProteoTech Inc. announced today that ... Dr. Luke Esposito, Director of In Vitro Screening, ... Parkinson,s Diseases, to be held in Prague, Czech Republic, March ... Snow will give an oral presentation discussing promising results pertaining ...

Other Medicine News:Health News:L.A.'s Newest Advanced Imaging Center Houses New GE 64-Slice PET/CT and 3T MRI in Spa-Inspired Environment 2 Health News:L.A.'s Newest Advanced Imaging Center Houses New GE 64-Slice PET/CT and 3T MRI in Spa-Inspired Environment 3 Health News:ULURU Inc. Announces Senior Management Change 2 Health News:SecureWorks Partners With ETEK International to Provide Security Services to the South American and Latin American Markets 2 Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 2 Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 3 Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 4 Health News:Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages 5 Health News:ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009 2

L.A.'s Newest Advanced Imaging Center Houses New GE 64-Slice PET/CT and 3T MRI in Spa-Inspired Environment SOX9 renders melanomas sensitive to retinoic acid and stops tumor growth ULURU Inc. Announces Senior Management Change SecureWorks Partners With ETEK International to Provide Security Services to the South American and Latin American Markets Frost & Sullivan Recognizes ValveXchange's Pioneering Heart Valve Technology for Unique Long-term Management and Future Replacement Advantages ProteoTech to Present at 9th International Conference for Alzheimer's and Parkinson's Disease - Prague, Czech Republic, March 11-15, 2009

... The Rubicon Filter System is an ... removes much of the debris that may ... Filter System comprises several components. The first ... is a capture catheter. Other ancillary components ...

... is a simulator for intraocular surgery. The ... surgeon the feeling that he is experiencing ... surgeon uses instruments that feel and function ... through the EYESI microscope is similar to ...

One inch disposable patch electrode uses a specially formulated adhesive solid gel. Reusable lead wire with snap connector provides economic benefits. Ideal for sleep studies where leg movement or EK...

... Made with elastic fabric, these head ... you need to begin testing. Each Electro-Cap ... to the International 10-20 System. When you ... you are using with your head cap ...

Medicine Products:

Rubicon Filter EYESI Ophthalmosurgical Simulator 60 Lead wire with snap connector Head Cap System II Easy II

New Data Examines the Effect of Adding a Statin to Optimized Treatment for Patients with Advanced Hea...(gression ofatherosclerosis to prevent on...),Health